Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Wedbush initiated coverage on Zenas BioPharma, Inc. (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company focused ...

As previously reported, Wedbush initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $35 price target The firm notes its ...

D-Wave Quantum fell for a third straight day on Thursday, losing 18.02 percent to end at $8.69 each as investors sold off ...

The DEA is "out of touch" and resistant to reform, stated Ben Kovler. Yet, amid this uncertainty, MMJ International Holdings ...

Sun exposure can help most people boost their vitamin D levels. Your body makes vitamin D when cells in your skin come into ...

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...

SaveHealth reports on the third-party companies that work to negotiate discounts with pharmacies and pharmacy benefit ...

ASX health stocks broke their losing streak this week, while it was a big week for Nanosonics, Neurizon and Sigma.

Enhanced Regenerative Potential: Stem cell-derived exosomes accelerate wound healing and tissue regeneration. Market Research Future Market Research Future +1 855-661-4441 email us here Visit us on ...

Shares of Zenas BioPharma (NASDAQ:ZBIO) rose on Thursday after Wedbush launched the newly IPO’ed biotech's coverage with an ...

Listening to the two major parties a few days out from the budget, you’d think there is no significant constituency in this country for cutting government spending.